Inhibrx Biosciences, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Mark P. Lappe and CFO Kelly D. Deck certified the Q2 2026 10-Q filing (quarter ended June 30, 2026) on August 13, 2026 pursuant to Sarbanes-Oxley Sections 302 and 906. Both certifications attest that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective; no material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certification exhibits with no substantive disclosure of business changes, transactions, or control failures—standard periodic regulatory compliance.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.